Eikon Therapeutics, Inc. (EIKN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the date of February 6, 2026. The filing documents the closing of the Company's initial public offering (IPO) of common stock on The Nasdaq Stock Market LLC. In connection with the IPO, Eikon Therapeutics, Inc. filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws with the State of Delaware, effective immediately prior to the closing.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes and the IPO event rather than financial performance data.
Material Changes
- Corporate Structure: The Company amended and restated its Certificate of Incorporation and Bylaws to align with its status as a publicly traded entity.
- Public Listing: Common stock ($0.0001 par value) began trading under the symbol "EIKN" on The Nasdaq Stock Market LLC.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard incorporation of the Restated Certificate and Bylaws by reference. No unusual items or contingencies are detailed in this specific report.
Key Facts for Investor Verification
- Verify the final IPO share price and total capital raised in the related Form S-1 or prospectus.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for details on authorized share count and anti-takeover provisions.
- Confirm the exact number of shares outstanding post-IPO.
- Check subsequent filings for the Company's cash position and burn rate following the IPO closing.